Multivalent Porous Silicon Nanoparticles Enhance the Immune Activation Potency of Agonistic CD40 Antibody

被引:71
|
作者
Gu, Luo [1 ]
Ruff, Laura E. [2 ]
Qin, Zhengtao [1 ]
Corr, Maripat [3 ]
Hedrick, Stephen M. [4 ]
Sailor, Michael J. [1 ]
机构
[1] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
CROSS-PRESENTATION; DRUG-DELIVERY; QUANTUM DOTS; CELLS; MICROPARTICLES; IMMUNOTHERAPY; RESPONSES; INTERNALIZATION; DISSOLUTION; INDUCTION;
D O I
10.1002/adma.201200776
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
One of the fundamental paradigms in the use of nanoparticles to treat disease is to evade or suppress the immune system in order to minimize systemic side effects and deliver sufficient nanoparticle quantities to the intended tissues. However, the immune system is the body's most important and effective defense against diseases. It protects the host by identifying and eliminating foreign pathogens as well as self-malignancies. Here we report a nanoparticle engineered to work with the immune system, enhancing the intended activation of antigen presenting cells (APCs). We show that luminescent porous silicon nanoparticles (LPSiNPs), each containing multiple copies of an agonistic antibody (FGK45) to the APC receptor CD40, greatly enhance activation of B cells. The cellular response to the nanoparticle-based stimulators is equivalent to a 30-40 fold larger concentration of free FGK45. The intrinsic near-infrared photoluminescence of LPSiNPs is used to monitor degradation and track the nanoparticles inside APCs.
引用
收藏
页码:3981 / 3987
页数:7
相关论文
共 50 条
  • [1] A combined effect of immune checkpoint inhibitors and a CD40 agonistic antibody in a pancreatic cancer mouse model
    Ichikawa, Juri
    Kawano, Kuniyuki
    Kato, Shingo
    Kurotaki, Daisuke
    Kuroishikawa, Ryo
    Kawase, Wataru
    Yoshida, Haruka
    Hiroshima, Yukihiko
    Endo, Itaru
    Maeda, Shin
    Nakajima, Atsushi
    Tamura, Tomohiko
    CANCER SCIENCE, 2024, 115 : 763 - 763
  • [2] Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
    Richman, Lee P.
    Vonderheide, Robert H.
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (01) : 19 - 26
  • [3] Fibroblast activation protein (FAP)selective delivery of CD40 agonistic DARPin molecule for tumor-localized immune activation
    Rigamonti, Nicolo
    Schlegel, Anja
    Barsin, Sophie
    Schwestermann, Jonas
    Mangold, Susanne
    Kaufmann, Yvonne
    Zitt, Christof
    Veitonmaki, Niina
    Levitsky, Victor
    Metz, Clara
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Agonistic antibody to CD40 blocks human lymphocyte apoptosis in an in vitro model of sepsis
    Schwulst, SJ
    Chang, K
    Osborne, D
    Ferguson, T
    Hotchkiss, R
    CRITICAL CARE MEDICINE, 2005, 33 (12) : A136 - A136
  • [5] Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer
    Fransen, Marieke F.
    Cordfunke, Robert A.
    Sluijter, Marjolein
    van Steenbergen, Mies J.
    Drijfhout, Jan W.
    Ossendorp, Ferry
    Hennink, Wim E.
    Melief, Cornelis J. M.
    VACCINE, 2014, 32 (15) : 1654 - 1660
  • [6] Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade
    Wu, Richard C.
    Luke, Jason J.
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 9 - 11
  • [7] The role of CD40 in CD40L-and antibody-mediated platelet activation
    Langer, F
    Ingersoll, SB
    Amirkhosravi, A
    Meyer, T
    Siddiqui, FA
    Ahmad, S
    Walker, JM
    Amaya, M
    Desai, H
    Francis, JL
    THROMBOSIS AND HAEMOSTASIS, 2005, 93 (06) : 1137 - 1146
  • [8] Immune cell activation by novel hexavalent CD40 agonist APG1233 compared to trimeric formats or agonistic anti-CD40 antibodies
    Richards, D. M.
    Merz, C.
    Sykora, J.
    Thiemann, M.
    Beyer, T.
    Kuehn, S.
    Fricke, H.
    Gieffers, C.
    Hill, O.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S99 - S99
  • [9] Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization
    White, Ann L.
    Dou, Lang
    Chan, H. T. Claude
    Field, Vikki L.
    Mockridge, C. Ian
    Moss, Kane
    Williams, Emily L.
    Booth, Steven G.
    French, Ruth R.
    Potter, Elizabeth A.
    Butts, Cherie
    Al-Shamkhani, Aymen
    Cragg, Mark S.
    Verbeek, J. Sjef
    Johnson, Peter W. M.
    Glennie, Martin J.
    Beers, Stephen A.
    JOURNAL OF IMMUNOLOGY, 2014, 193 (04): : 1828 - 1835
  • [10] Systemic immune response to a CD40 agonist antibody in nonhuman primates
    Caudell, David L.
    Dugan, Gregory O.
    Babitzki, Galina
    Schubert, Christine
    Braendli-Baiocco, Annamaria
    Wasserman, Ken
    Acona, Gonzalo
    Stern, Martin
    Passioukov, Alexandre
    Cline, J. Mark
    Charo, Jehad
    JOURNAL OF LEUKOCYTE BIOLOGY, 2024, 115 (06) : 1084 - 1093